| Drug General Information |
| Drug ID |
D0TU7V
|
| Former ID |
DIB014783
|
| Drug Name |
MB-12066
|
| Synonyms |
B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence
|
| Indication |
Obesity [ICD9: 278; ICD10:E66]
|
Phase 2 |
[1]
|
|---|
| Company |
Mazence Inc
|
| Target and Pathway |
| Target(s) |
NAD-dependent deacetylase sirtuin-1 |
Target Info |
Modulator |
|
|---|
|
KEGG Pathway
|
FoxO signaling pathway
|
|
AMPK signaling pathway
|
|
Glucagon signaling pathway
|
|
Amphetamine addiction
|
|
MicroRNAs in cancer
|
|
PANTHER Pathway
|
p53 pathway
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
Signaling events mediated by HDAC Class III
|
|
E2F transcription factor network
|
|
HIF-2-alpha transcription factor network
|
|
Signaling events mediated by HDAC Class I
|
|
FoxO family signaling
|
|
Regulation of Androgen receptor activity
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
RORA activates gene expression
|
|
Regulation of HSF1-mediated heat shock response
|
|
Circadian Clock
|
|
WikiPathways
|
Integrated Pancreatic Cancer Pathway
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Integrated Breast Cancer Pathway
|
|
SREBP signalling
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02029586) Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis. U.S. National Institutes of Health. |
|---|
